Therapy News and Research

RSS

Better vision ahead for many diabetic retinopathy patients

A nationwide, government-sponsored study finds that people with a common form of diabetic retinopathy can benefit from a medication first developed to combat another potentially blinding disease, age-related macular degeneration (AMD). Treating diabetic macular edema (DME) with ranibizumab (Lucentis) eye injections, plus laser treatment if needed, appears to result in better vision than laser treatment alone, according to the Diabetic Retinopathy Clinical Research (DRCR) Network study published today in Ophthalmology online, the journal of the American Academy of Ophthalmology (Academy). DME is the main cause of vision loss in people with diabetes mellitus.

27 Apr 2010

Interim results from Phase I clinical trial of PLX-PAD for treatment of CLI

Pluristem Therapeutics Inc. today announced interim top-line results from its Phase I clinical trials utilizing its placenta-derived cell therapy product, PLX-PAD, for the treatment of critical limb ischemia, the end-stage of peripheral artery disease. The interim data demonstrated that PLX-PAD is safe, well tolerated and effective.

27 Apr 2010

Pharmacological suppression of nonsense mutations effective in treating genetic defects

Genetic mutation can disrupt the way human cells make proteins, which in turn leads to inherited disease. David Bedwell, a professor in the University of Alabama at Birmingham (UAB) Department of Microbiology, says scientists are closer than ever to producing drugs that fix this disrupted-protein pathway and drastically improving treatment of genetic disease.

27 Apr 2010

MicroStockProfit.com announces investment report featuring BioElectronics

MicroStockProfit.com announces an investment report featuring BioElectronics Corp. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

27 Apr 2010

Kinetic Concepts' first-quarter 2010 total revenues increase 3% to $485.8M

Kinetic Concepts, Inc. today reported first quarter 2010 total revenue of $485.8 million, an increase of 3% from the first quarter of 2009. Foreign currency exchange movements favorably impacted total revenue for the first quarter of 2010 by 2% compared to the corresponding period of the prior year.

27 Apr 2010

IBS patients treated with cognitive behavior therapy have positive response: Study

A significant proportion of irritable bowel syndrome patients treated with cognitive behavior therapy have a positive response within four weeks of treatment, according to a new study in Clinical Gastroenterology and Hepatology, the official journal of the American Gastroenterological Association Institute.

27 Apr 2010

KCI applauds FDA for launching medical device home use initiative

KCI applauds the FDA for launching this important initiative to ensure that complex medical devices are used safely in the home by caregivers and patients. We have made it our priority and unwavering responsibility to help caregivers and patients understand how to use our advanced treatments safely. This includes offering a robust education and training program, employing highly trained clinical support staff and providing easy-to-read, patient-specific labeling.

27 Apr 2010

CocE exhibits potential for clinical treatment of cocaine toxicity

Cocaine toxicity due to drug overdose results in more than half a million emergency room visits annually. Despite these alarming statistics, there is no Food and Drug Administration-approved pharmacotherapy specifically designed to treat cocaine toxicity. Emergency medical personnel are limited to treating only the immediate life-threatening symptoms of patients, while toxic levels of cocaine and its metabolic break-down products persist and continue to damage the cardiovascular system, liver and brain.

27 Apr 2010

Advair to remain favored fixed-dose LABA/ICS combination therapy through 2013 for asthma and COPD

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, despite increased competition from several emerging agents, GlaxoSmithKline's Advair will remain surveyed pulmonologists' and primary care physicians' (PCPs) favored fixed-dose long-acting beta2 agonist (LABA)/inhaled corticosteroid (ICS) combination inhaler through 2013 for the treatment of asthma and chronic obstructive pulmonary disease (COPD).

27 Apr 2010

Melanin-covered nanoparticles may protect bone marrow from harmful radiation therapy effects: Research

Tiny, melanin-covered nanoparticles may protect bone marrow from the harmful effects of radiation therapy, according to scientists at Albert Einstein College of Medicine of Yeshiva University who successfully tested the strategy in mouse models.

27 Apr 2010

Vital stem cells extracted during heart bypass surgery can help repair damaged heart muscle: BHF

Scientists have for the first time succeeded in extracting vital stem cells from sections of vein removed for heart bypass surgery. Researchers funded by the British Heart Foundation found that these stem cells can stimulate new blood vessels to grow, which could potentially help repair damaged heart muscle after a heart attack.

27 Apr 2010

LCT receives grant of $500,000 for Phase II clinical trial of DIABECELL in New Zealand

Living Cell Technologies Limited, a global company pioneering the development of a cell implant to treat diabetes, has received a grant of US$500,000 for its on-going Phase II clinical trial of DIABECELL in New Zealand from the Juvenile Diabetes Research Foundation International, a world leader in setting the agenda for diabetes research and the largest charitable funder and advocate for research in type 1 diabetes.

27 Apr 2010

Men with erectile dysfunction, low testosterone at higher risk of death from cardiovascular disease

Research presented at the European Congress of Endocrinology shows for the first time that men with erectile dysfunction and low testosterone have a higher than normal risk of dying from cardiovascular disease. Further work from the same research group shows that obesity is also associated with an impairment of blood flow to the penis, which in turn is also associated with cardiovascular disease in men with erectile dysfunction.

27 Apr 2010

Evotec to receive EUR 1.5M from German BMBF for advancing H3 receptor antagonist programme

Evotec AG today announced that it will receive funding of up to EUR 1.5 million from the German Federal Ministry of Education and Research (BMBF) to advance its H3 receptor antagonist programme into the clinic.

27 Apr 2010

GORE VIABIL Biliary Endoprosthesis receives European CE Mark approval for expanded indication

W. L. Gore & Associates (Gore) today announced it has received European CE Mark approval for an expanded indication of the GORE® VIABIL® Biliary Endoprosthesis that allows removal of the device up to 12 months after implantation for the treatment of benign or malignant biliary strictures. The GORE® VIABIL® Biliary Endoprosthesis first received CE Mark approval in December 1999 and U.S. Food and Drug Administration (FDA) approval in January 2002 for the treatment of biliary strictures due to malignant neoplasms.

27 Apr 2010

FDA grants NexMed clearance for HCC Phase 2 trial for PrevOnco

NexMed, Inc., a specialty CRO with a pipeline of products based on the NexACT® technology, today announced that the U.S. Food & Drug Administration (FDA) has cleared the Company to proceed with the proposed Phase 2 trial of PrevOnco™, its proprietary cancer treatment for patients with advanced, unresectable hepatocellular carcinoma (HCC), or liver cancer. The FDA granted PrevOnco™ orphan drug status in August 2008, and in March 2010, NexMed filed its Investigational New Drug (IND) application for the product candidate.

27 Apr 2010

Nurses interrupted – leading to 12% rise in medication errors: study

In a study published in the journal Archives of Internal Medicine on the 26th of April the causes of “procedural failure and clinical error” by nurses in Australian hospitals were analyzed. The study found that nurses made at least one mistake or oversight in a whopping 80.2% of cases where they were administering drugs or other therapy to patients. These mistakes could range from not checking the patient’s identity before giving the drug to not washing hands. Researchers say that in some cases these mistakes could be fatal.

27 Apr 2010

ERCC1 Analysis guides patient treatment decisions

Moffitt Cancer Center announces steadily growing interest in the ERCC1 Analysis, the first test developed for selecting chemotherapy for Non Small Lung Cancer patients. Each year, more than 200,000 Americans are diagnosed with lung cancer.

26 Apr 2010

Researchers show how analgesia should be carried out for children and adolescents

Properly performed analgesia protects children from pain and traumatization. In the current issue of Deutsches Ärzteblatt International, Christoph Neuhäuser and his colleagues show how analgesia for children and adolescents should be carried out.

26 Apr 2010

OSI Pharmaceuticals completes enrollment in Phase III clinical trial of Tarceva

OSI Pharmaceuticals, Inc. announced today that it has completed enrollment in the RADIANT study, a Phase III clinical trial testing Tarceva (erlotinib) as an adjuvant therapy in patients with Stage IB-IIIA non-small cell lung cancer who have undergone surgery and have EGFR-positive tumors.

26 Apr 2010

Therapy News and Research

Better vision ahead for many diabetic retinopathy patients

Interim results from Phase I clinical trial of PLX-PAD for treatment of CLI

Pharmacological suppression of nonsense mutations effective in treating genetic defects

MicroStockProfit.com announces investment report featuring BioElectronics

Kinetic Concepts' first-quarter 2010 total revenues increase 3% to $485.8M

IBS patients treated with cognitive behavior therapy have positive response: Study

KCI applauds FDA for launching medical device home use initiative

CocE exhibits potential for clinical treatment of cocaine toxicity

Advair to remain favored fixed-dose LABA/ICS combination therapy through 2013 for asthma and COPD

Melanin-covered nanoparticles may protect bone marrow from harmful radiation therapy effects: Research

Vital stem cells extracted during heart bypass surgery can help repair damaged heart muscle: BHF

LCT receives grant of $500,000 for Phase II clinical trial of DIABECELL in New Zealand

Men with erectile dysfunction, low testosterone at higher risk of death from cardiovascular disease

Evotec to receive EUR 1.5M from German BMBF for advancing H3 receptor antagonist programme

GORE VIABIL Biliary Endoprosthesis receives European CE Mark approval for expanded indication

FDA grants NexMed clearance for HCC Phase 2 trial for PrevOnco

Nurses interrupted – leading to 12% rise in medication errors: study

ERCC1 Analysis guides patient treatment decisions

Researchers show how analgesia should be carried out for children and adolescents

OSI Pharmaceuticals completes enrollment in Phase III clinical trial of Tarceva

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News